(Reuters) A tangle of high-stakes U.S. patent disputes over COVID-19 vaccines could be tamed by court rulings or grow even more complex next year. In the headlining fight, Moderna sued Pfizer and BioNTech in August, accusing them of infringing three patents on mRNA-related innovations Moderna said it developed before the COVID-19 pandemic. Pfizer and BioNTech responded earlier this month that Moderna had overstated its contributions to the field of mRNA technology. They asked a Massachusetts federal court to declare Moderna’s patents in the lawsuit invalid and dismiss the case.
COVID-19 vaccine patent battles continue into 2023
- Published Dec 27, 2022